According to filings with the U.S. Securities and Exchange Commission, GT Medical Technologies has raised $100 Million in new Series E funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures

About GT Medical Technologies
GT Medical Technologies is redefining the treatment of operable brain tumors. Founded by brain tumor specialists and medical device innovators, GT Medical was created to address critical gaps in how these tumors are treated – and to challenge the limitations of conventional therapies. We develop innovative, surgically integrated therapies designed to deliver treatment with greater precision, improve clinical outcomes, and elevate the standard of care for patients. GammaTile®, our first FDA-cleared technology, exemplifies our mission. Designed for patients with operable brain tumors, GammaTile is a surgically implantable, bioabsorbable tile-based radiation therapy placed directly into the tumor cavity at the time of tumor resection. By delivering radiation from within the surgical cavity, GammaTile provides precise, localized tumor control while limiting exposure to surrounding healthy brain tissue. This intraoperative approach is supported by published data from multiple institutions that show strong efficacy and safety data. Since its full U.S. market launch in March 2020, GammaTile has been adopted by numerous leading cancer centers across academic and community settings, reflecting growing confidence in GT Medical’s approach and the clinical impact of its technology.

To learn more, visit https://gammatile.com/
Linkedin: https://www.linkedin.com/company/gt-medical-technologies-inc/

Contact:
Per Langoe, Chief Executive Officer
https://www.linkedin.com/in/per-langoe-62a2244/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.